Latest News - Dementia & Cognitive Disorders

Friday, September 21, 2018

Alzheimer’s Drug Discovery Foundation Meeting Reports Advances

At the 19th International Conference on Alzheimer’s Drug Discovery, the focus was on gene therapy and alternative modalities for treating patients with neurodegenerative diseases, as well as the…

Read the full story

Thursday, September 20, 2018

FDA Analysis Finds No New or Unexpected Safety Risks of Pimavanserin:Benefits Outweigh Risks

The Food and Drug Administration (FDA) announced that there are no new safety concerns for pimavanserin (Nuplazid; Acadia Pharma, San Diego, CA). Pimavanserin is approved for the treatment of psychoti…

Read the full story

Wednesday, September 19, 2018

Flortaucipir Positron Emission Tomography Imaging Differentiates Alzheimer Disease From Other Neurodegenerative Diseases

In a cross-sectional, multicenter international trial, (JAMA. 2018;320(11):1151-1162.) it was shown that neuroimaging with [18F]flortaucipir-positron emission tomography (PET) was able to sensiti…

Read the full story

Wednesday, August 29, 2018

Breakthrough Device Designation Granted for Digital and Adaptive Reminiscence Therapy

The Food and Drug Administration (FDA) has designated a digital therapy for persons with Alzheimer’s Disease (AD) as a breakthrough device. This designation, a provision of the 21st Century Cure…

Read the full story

Monday, August 20, 2018

Long-Term Safety and Efficacy of Valbenazine for Patients With Tardive Dyskinesia

Long-term results for valbenazine (Ingrezza; Neurocrine Biosciences, San Diego, CA), a treatment for patients with tardive dyskinesia (TD), are being presented at the 2018 World Congress on Parkinson&…

Read the full story

Wednesday, August 08, 2018

Funding Received for Phase 2 Trial of Xanomeline-Tropsium Chloride

A $42-million financing round has been completed and will be used to finance a phase 2 trial of xanomeline-tropsium chloride (KarXT; Karuna, Boston, MA) for treatment of persons with schizophrenia. …

Read the full story

Tuesday, August 07, 2018

Braintest App Has Equivalent Sensitivity and Specificity as SAGE Test for Mild Cognitive Impairment

There is an app (BrainTest, Columbus, OH) used to detect mild cognitive impairment (MCI). It is a clinically validated, digital version of the paper and pen Self-Administered Gerocognitive Exam (SAGE)…

Read the full story

Monday, July 30, 2018

Breaching the Blood-Brain Barrier: A Potential New Treatment Modality

In a small, yet groundbreaking, clinical trial, MR-guided focused ultrasound (MRgFUS) (ExablateNeuro; Insightec, Miami FL) was used to open the blood-brain barrier (BBB) safely in 5 persons with mild-…

Read the full story

Monday, July 30, 2018

Aggressive Treatment of Hypertension Promotes Healthy Brains and Hearts

Aggressive lowering of systolic blood pressure (BP) reduces the risk of mild cognitive impairment (MCI) and combined MCI and dementia. In the SPRINT trial (NCT01206062), 2 strategies for managing high…

Read the full story

Friday, July 27, 2018

Positive Results in Phase 2 Trial of BAN2401 for Treatment of Persons With Alzheimer’s Disease

Detailed results of a phase 2 study (NCT01767311) of BAN2401 (Eisai, Woodcliff Lake, NJ and Biogen, Cambridge, MA) were presented at the Alzheimer's Association International Conference (AAIC) 201…

Read the full story

Thursday, July 26, 2018

Crenezumab and Gantenerumab In Phase 3 Trials for Treating Persons with Alzheimer’s Disease

Crenezumab and Gantenerumab are 2 monoclonal antibodies directed against amyloid-ß (Aß) soluble and oligomeric forms. Crenezumab more specifically targets oligomers, whereas ganteneru…

Read the full story

Thursday, July 26, 2018

Phase 2/3 Clinical Trial of Trigriluzole for Alzheimer's Disease Initiated

A Phase 2/3 clinical trial of trigriluzole (BHV-4157; Biohaven, Cambridge, MA for treatment of patients with mild-to-moderate Alzheimer's disease (AD) has been initiated in collaboration with the …

Read the full story

Wednesday, July 25, 2018

Gut Bacteria and Lipid Metabolism May Influence Alzheimer’s Disease and Dementia

Several studies at the Alzheimer’s Association International Conference (AAIC) 2018 showed that lipid, cholesterol, and bile acid metabolism correlate with biomarkers for and clinical findings o…

Read the full story

Tuesday, July 24, 2018

Having Children May Be Associated With Reduced Risk of Dementia and Other Sex-Specific Differences in Dementia

While it has long been known that AD is more prevalent in women than men (3:2) in the US, the reasons for this are not fully understood; theories include women's longer lifespans, social factors, …

Read the full story

Monday, July 23, 2018

Alzheimer’s Association Releases First Clinical Evaluation Guideline

New evidence-based consensus guidelines for the evaluation of cognitive-behavioral symptoms of Alzheimer's disease (AD) and other dementias have been released and strongly encourage early diagnosi…

Read the full story
Load More